CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model

International Immunopharmacology

Volumn 10, Issue 4, 2010, Pages 412-421

  Zimmerman, Daniel H ^a   Taylor, Patricia ^b   Bendele, Alison ^c   Carambula, Roy ^d   Duzant, Yvonne ^d   Lowe, Valeria ^e   O'Neill, Sean P ^e   Talor, Eyal ^d   Rosenthal, Kenneth S ^b  

^a CEL SCI Corporation   (United States)

^b Northeast Ohio Medical University   (United States)

^c BoulderBiopath   (United States)

^d CEL SCI Corporation   (United States)

^e Advanced Biotechnologies Inc   (United States)

Author keywords

Collagen induced arthritis; Regulation of cytokines in autoimmunity; Rheumatoid arthritis; Therapeutic vaccine; Vaccines for autoimmunity

Indexed keywords

ANTIGEN; BETA 2 MICROGLOBULIN; CEL 2000; COLLAGEN TYPE 2; EPITOPE; ETANERCEPT; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; PEPTIDE VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COW; DBA MOUSE; DISEASE COURSE; DRUG SAFETY; FOOT PAD; HISTOPATHOLOGY; LONG TERM CARE; MALE; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SWELLING; T LYMPHOCYTE; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CHEMOKINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLLAGEN TYPE II; CYTOKINES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOOT; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED DBA; MOLECULAR SEQUENCE DATA; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; VACCINES; VACCINES, SUBUNIT;

EID: 77949485280     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.12.016     Document Type: Article

References (63)

1. Dinarello C. Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis: a primer for clinicians. 3 rd edition (2002), Amgen Presss, Thousand Oaks CA
2. Massa M., Passalia M., Manzoni S.M., Campanelli R., Ciardelli L., Yung G.P., et al. Differential recognition of heat-shock protein DNAJ-derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis. Arthritis Rheum 56 (2007) 1648
3. Krco C.J., Pawelski J., Harders J., McCormick D., Griffiths M., Luthra H.S., et al. Characterization of the antigenic structure of human type II collagen. J Immunol 156 (1996) 2761
4. Myers L.K., Terato K., Seyer J.M., Stuart J.M., and Kang A.H. Characterization of a tolerogenic T cell epitope of type II collagen and its relevance to collagen-induced arthritis. J Immunol 149 (1992) 1439
5. Brand D.D., Marion T.N., Myers L.K., Rosloniec E.F., Watson W.C., Stuart J.M., et al. Autoantibodies to murine type II collagen in collagen-induced arthritis: a comparison of susceptible and nonsusceptible strains. J Immunol 157 (1996) 5178
6. Honda A., Suzuki K., Sercarz E.E., Kumar V., Ametani A., Matsumoto T., et al. Vaccination with an immunodominant peptide of bovine type II collagen induces an anti-TCR response, and modulates the onset and severity of collagen-induced arthritis. Int Immunol 16 (2004) 737
7. Svendsen P., Andersen C.B., Willcox N., Coyle A.J., Holmdahl R., Kamradt T., et al. Tracking of proinflammatory collagen-specific T cells in early and late collagen-induced arthritis in humanized mice. J Immunol 173 (2004) 7037
8. Zanelli E., Krco C.J., and David C.S. Critical residues on HLA-DRB1*0402 HV3 peptide for HLA-DQ8-restricted immunogenicity: implications for rheumatoid arthritis predisposition. J Immunol 158 (1997) 3545
9. Krco C.J., Watanabe S., Harders J., Griffths M.M., Luthra H., and David C.S. Identification of T cell determinants on human type II collagen recognized by HLA-DQ8 and HLA-DQ6 transgenic mice. J Immunol 163 (1999) 1661
10. Kim H.Y., Kim W.U., Cho M.L., Lee S.K., Youn J., Kim S.I., et al. Enhanced T cell proliferative response to type II collagen and synthetic peptide CII (255-274) in patients with rheumatoid arthritis. Arthritis Rheum 42 (1999) 2085
11. Tang B., Myers L.K., Rosloniec E.F., Whittington K.B., Stuart J.M., and Kang A.H. Characterization of signal transduction through the TCR-zeta chain following T cell stimulation with analogue peptides of type II collagen 260-267. J Immunol 160 (1998) 3135
12. Rosloniec E.F., Brand D.D., Myer L.K., Esaki Y., Whittington K.B., Zaller D.M., et al. Induction of autoimmune arthritis in HLA-DR4 (DRB1*0401) transgenic mice by immunization with human and bovine type II collagen. J Immunol 160 (1998) 2573
13. Myers L.K., Tang B., Rosloniec E.F., Stuart J.M., Chiang T.M., and Kang A.H. Characterization of a peptide analog of a determinant of type II collagen that suppresses collagen-induced arthritis. J Immunol 161 (1998) 3589
14. Kannan K., Ortmann R.A., and Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 12 (2005) 167
15. Hegen M., Keith Jr. J.C., Collins M., and Nickerson-Nutter C.L. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis 67 (2008) 1505
16. Williams R.O. Collagen-induced arthritis in mice. Methods Mol Med 136 (2007) 191
17. van Eden W., Wagenaar-Hilbers J.P., and Wauben M.H. Adjuvant arthritis in the rat. Curr Protoc Immunol (2001) Chapter 15 Unit 15/4
18. Trentham D.E., Dynesius-Ttrentham R.A., Orav E.J., Combitchi D., Lorenzo C., Sewell K.L., et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261 (1993) 1727
19. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 337 (1997) 141
20. Franklin C.M. Clinical experience with soluble TNF p75 receptor in rheumatoid arthritis. Semin Arthritis Rheum 29 (1999) 172
21. Hildner K., Edelson B.T., Purtha W.E., Diamond M., Matsushita H., Kohyama M., et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322 (2008) 1097
22. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198 (2003) 1951
23. Kikly K., Liu L., Na S., and Sedgwick J.D. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 18 (2006) 670-675
24. Martinez G.J., Nurieva R.I., Yang X.O., and Dong C. Regulation and function of proinflammatory TH17 cells. Ann N Y Acad Sci 1143 (2008) 188-211.:188
25. Shevach E.M. Immunology. Regulating suppression. Science 322 (2008) 202
26. Romagnani S. Regulatory T cells: which role in the pathogenesis and treatment of allergic disorders?. Allergy 61 1 (2006 Jan) 3-14
27. Akdis C.A., and Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol 123 4 (2009 Apr) 735-746
28. Stratton KR, Durch JD, and Lawrence RS. 2000. Book, Vaccines for the 21st century: A Tool for Decision Making. National Academy Press, ed.
29. Cihakova D., Barin J.G., Baldeviano G.C., Kimura M., Talor M.V., Zimmerman D.H., et al. L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart. Int Immunopharmacol 8 (2008) 624
30. Rosenthal, K. S., H. Mao, W. I. Horne, C. Wright, and D. Zimmerman. 1998. Immunization with a L.E.A.P.S. heteroconjugate vaccine containing a CTL epitope and a peptide from beta-2-microgl.
31. Goel N., Rong Q., Zimmerman D., and Rosenthal K.S. A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection. Vaccine 21 (2003) 4410
32. Goel N., Zimmerman D.H., and Rosenthal K.S. Ligand epitope antigen presentation system vaccines against herpes simplex virus. Front Biosci 966 (2005)
33. Zimmerman D.H., Bergmann K.F., Rosenthal K.S., and Elliott D.A. A new approach to T cell activation: natural and synthetic conjugates capable of activating T cells. Vac Res 5 (1996) 91-102
34. Zimmerman D.H., Morris S., Rouse W.K.F.W., Elliott D.A., and Rosenthal K.S. Immunization with peptide heteroconjugates primes a TH1 associated antibody (IgG2a) response which recognizes the native epitope on the 38 kDa protein of Mycobacterium tuberculosis. Vac Res 5 (1996) 103-113
35. Zimmerman D.H., Mundon F.K., Croson S.E., Henchal L.S., Docherty J.J., and O'Neill S.P. Identification and typing of herpes simplex virus types 1 and 2 by monoclonal antibodies, sensitivity to the drug (E)-5-(-2-bromovinyl)-2′-deoxyuridine an restriction endonuclease analysis of viral DNA. Med Virol 15 (1985) 215-222
36. Charoenvit Y., Brice G.T., Bacon D., Majam V., Williams J., Abot E., et al. A small peptide (CEL-1000) derived from the beta-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner. Antimicrob Agents Chemother 48 (2004) 2455
37. Charoenvit Y., Goel N., Whelan M., Rosenthal K.S., and Zimmerman D.H. CEL-1000-a peptide with adjuvant activity for Th1 immune responses. Vaccine 10 (2004) 2368
38. SF p17) and peptide segments of human β-2-microglobulin or MHC II β chain. Vaccine 19 32 (2001) 4750-4759
39. Pisarev, Parajuli V.M.P., Mosley R.L., Sublet J., Kelsey L., Zimmerman D., et al. FLT3 ligand and an IL-1-β bioactive heteroconjugate as adjuvants for a type 1 cell mediated immune response to HIV gag p17 peptide. Vaccine 20 (2002) 2358-2368
40. Zimmerman D., and Rosenthal K. The L.E.A.P.S. approach to vaccine development. Front Biosci 10 (2005) 790-798
41. Zalevsky J., Secher T., Ezhevsky S.A., Janot L., Steed P.M., O'Brien C., et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 179 3 (2007) 1872-1883
42. Parham P., Androlewicz M.J., Holmes N.J., and Rothenberg B.E. Arginine 45 is a major part of the antigenic determinant of human â2-microglobulin recognized by mouse monoclonal antibody BBM1. J Biol Chem 258 (1983) 6179-6186
43. Cammarota G., Scheirle A., Takacs B., Doran D.M., Knorr R., Bannwarth W., et al. Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules. Nature 356 (1992) 799-801
44. Konig R Huang LY Germain RN MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binging site for CD8 Nature 356:796-8.
45. Taylor, P, G Koski, P. Cohen, DH Zimmerman KS Rosenthal (2009) J-L.E.A.P.S.™ vaccines initiate murine Th1 responses by activating dendritic cells. (Submitted for publication).
46. Martinez G.J., Nurieva R.I., Yang X.O., and Dong C. Regulation and function of proinflammatory Th17 cells. Ann NY Acad Sci 1143 (2008) 188-211
47. Murphy C.A.L., CL C.Y., Blumenschein W., McClanahan T., Kastelein R.A., Sedgwick J.D., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198 (2003) 1951-1957
48. Ooi J.D., Phoon R.K., Holdsworth S.R., and Kitching A.R. IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen. J Am Soc Nephrol 20 (2009) 925-927
49. Stumhofer J.S., Laurence A., Wilson E.H., Huang E., Tato C.M., Johnson L.M., et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells curing chronic inflammation of the central nervous system. Nat Immunol 7 (2006) 937-945
50. Jaen O., Rullé S., Bessis N., Zago A., Boissier M.C., and Falgarone G. Dendritic cells modulated by innate immunity improve collagen-induced arthritis and induce regulatory T cells in vivo. Immunology 126 (2008) 35-44
51. Ozato K., Tsujimura H., and Tamura T. Toll-like receptor signaling and regulation of cytokine gene expression in the immune system. Biotechniques 70 72 (2002) 66-68 Oct
52. Siegrist C.A. Blame vaccine interference, not neonatal immunization, for suboptimal responses after neonatal diphtheria, tetanus, and acellular pertussis immunization. J Pediatr 153 (2008) 305-307
53. Schmitt H.J., Zepp F., Müschenborn S., Sümenicht G., Schuind A., Beutel K., et al. Immunogenicity and reactogenicity of a Haemophilus influenzae type B tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations. Eur J Pediatr 157 (1998) 208-214
54. Lagos R., Kotloff K., Hoffenbach A., San Martin O., Abrego P., Ureta A.M., et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type B conjugate antigens in two-, four- and six-month-old Chilean infants. Pediatr Infect Dis J 17 (1998) 294-304
55. Peeters C.C., Tenbergen-Meekes A.M., Poolman J.T., Beurret M., Zegers B.J., and Rijkers G.T. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun 59 (1991) 3504-3510
56. Pines E., Barrand M., Fabre P., Salomon H., Blondeau C., Wood S.C., et al. New acellular pertussis-containing paediatric combined vaccines. Vaccine 17 (1999) 650-656
57. Boot HJ, Schipper CM. Simultaneous vaccination with prevenar and multicomponent vaccines for children: 2009 interference or no interference? Hum Vaccin. 205:15-17.
58. O'Brien K.L., Hochman M., and Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?. Lancet Infect Dis 7 (2007) 597-606
59. Street N.E., and Mosmann T.R. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J 5 (1991) 171-177
60. Halasa N.B., O'Shea A., Shi J.R., LaFleur B.J., and Edwards K.M. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr 153 (2008) 327-332
61. Gizurarson S. Clinically relevant vaccine-vaccine interactions: a guide for practitioners. BioDrugs 9 (1998) 443-453
62. Knuf M., Schmitt H.J., Wolter J., Schuerman L., Jacquet J.M., Kieninger D., et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr 152 (2008) 655-660
63. Toussirot E., and Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother 5 3 (2004) 581-594